2. 筋萎縮性側索硬化症 Amyotrophic lateral sclerosis Clinical trials / Disease details


臨床試験数 : 645 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

  
15 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05003921
(ClinicalTrials.gov)
December 20226/8/2021Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intrathecal Injection for ALSSafety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intrathecal Injection for the Treatment of Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisBiological: AlloRxThe Foundation for Orthopaedics and Regenerative MedicineNULLSuspendedN/AN/AAll20Phase 1Antigua and Barbuda
2NCT05306457
(ClinicalTrials.gov)
May 8, 202221/12/2021CNS10-NPC-GDNF Delivered to the Motor Cortex for ALSHuman Neural Progenitor Cells Secreting Glial Cell Line-Derived Neurotrophic Factor (CNS10-NPC-GDNF) Delivered to the Motor Cortex for the Treatment of Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisBiological: CNS10-NPC-GDNFCedars-Sinai Medical CenterCalifornia Institute for Regenerative Medicine (CIRM)Recruiting18 YearsN/AAll16Phase 1United States
3NCT04518540
(ClinicalTrials.gov)
September 1, 20205/8/2020Explore Neuroprotective Effect of Lipoic Acid in Amyotrophic Lateral SclerosisRandomized, Parallel Safety and Efficacy Study of Lipoic Acid in Patients With Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisDrug: lipoic acid group;Drug: control groupSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityNULLRecruiting20 Years75 YearsAll150N/AChina
4ChiCTR2000035966
2019-10-102020-08-20Clinical efficacy of expanded autologous regulatory T cells infusion in amyotrophic lateral sclerosisClinical efficacy and safety of expanded autologous peripheral blood mononuclear cells in amyotrophic lateral sclerosis Amyotrophic lateral sclerosisCase series:T cell therapy + Herb Qu + Interleukin-2;Nanjing Hospital Affiliated to Nanjing University of traditional Chinese MedicineNULLRecruitingBothCase series:30;China
5NCT04744532
(ClinicalTrials.gov)
March 19, 20199/1/2021iPSC-based Drug Repurposing for ALS Medicine (iDReAM) StudyPhase 1/2 Study of Bosutinib in Patients With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisDrug: Bosutinib (Phase 1 part);Drug: Bosutinib (Phase 2 part)Kyoto UniversityTokushima University;Kitasato University;Tottori University;Nara Medical University;Toho University;Hiroshima University;PfizerRecruiting20 Years75 YearsAll49Phase 1/Phase 2Japan
6NCT03690791
(ClinicalTrials.gov)
January 9, 201913/9/2018Efficacy of Cannabinoids in Amyotrophic Lateral Sclerosis or Motor Neurone DiseaseA Randomised, Double-blind, Single-centre Study on the Safety, Tolerability and Efficacy of Cannabis Based Medicine Extract (MediCabilis CBD Oil) in Slowing the Disease Progression in Amyotrophic Lateral Sclerosis or Motor Neurone Disease PatientsAmyotrophic Lateral Sclerosis;Motor Neuron DiseaseDrug: MediCabilis CBD Oil;Drug: Placebo OilGold Coast Hospital and Health ServiceBOD AustraliaRecruiting25 Years80 YearsAll30Phase 3Australia
7NCT03944447
(ClinicalTrials.gov)
December 1, 20183/5/2019Outcomes Mandate National Integration With Cannabis as MedicineOutcomes Mandate National Integration With Cannabis as MedicineChronic Pain;Chronic Pain Syndrome;Chronic Pain Due to Injury;Chronic Pain Due to Trauma;Fibromyalgia;Seizures;Hepatitis C;Cancer;Crohn Disease;HIV/AIDS;Multiple Sclerosis;Traumatic Brain Injury;Sickle Cell Disease;Post Traumatic Stress Disorder;Tourette Syndrome;Ulcerative Colitis;Glaucoma;Epilepsy;Inflammatory Bowel Diseases;Parkinson Disease;Amyotrophic Lateral Sclerosis;Chronic Traumatic Encephalopathy;Anxiety;Depression;Insomnia;Autism;Opioid-use Disorder;Bipolar Disorder;Covid19;SARS-CoV Infection;COVID-19;Corona Virus Infection;CoronavirusDrug: Cannabis, Medical;Device: RYAH-Medtech InhalerOMNI Medical Services, LLCOMNI Medical Services IncRecruiting7 YearsN/AAll200000Phase 2United States
8NCT03268603
(ClinicalTrials.gov)
October 10, 201730/8/2017Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)A Phase II Study of Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral SclerosisALS;Amyotrophic Lateral SclerosisDrug: Autologous Adipose-derived Mesenchymal Stromal CellsMayo ClinicState of Minnesota Regenerative Medicine MinnesotaActive, not recruiting18 YearsN/AAll75Phase 2United States
9NCT03280056
(ClinicalTrials.gov)
August 28, 201729/8/2017Safety and Efficacy of Repeated Administrations of NurOwn® in ALS PatientsA Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Repeated Administration of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) in Participants With ALSAmyotrophic Lateral Sclerosis (ALS)Biological: NurOwn® (MSC-NTF cells);Other: Placebo;Other: Bone Marrow aspirationBrainstorm-Cell TherapeuticsCalifornia Institute for Regenerative Medicine (CIRM)Completed18 Years60 YearsAll263Phase 3United States
10NCT02943850
(ClinicalTrials.gov)
April 1, 201720/10/2016CNS10-NPC-GDNF for the Treatment of ALSHuman Neural Progenitor Cells Secreting Glial Cell Line-Derived Neurotrophic Factor (CNS10-NPC-GDNF) for the Treatment of Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisBiological: Stem cell (HPC) implantation;Device: Stereotactic surgical deviceCedars-Sinai Medical CenterCalifornia Institute for Regenerative Medicine (CIRM)Completed18 YearsN/AAll18Phase 1United States
11JPRN-UMIN000026221
2017/03/0201/03/2017Safety of perampanel in patients with motor neuron diseaseSafety of perampanel in patients with motor neuron disease - Safety of perampanel in patients with motor neuron disease amyotrophic lateral sclerosisOnce daily perampanel with dose escalation from 2mg to 8mg.Department of Neurology, Juntendo University School of MedicineNULLComplete: follow-up complete20years-oldNot applicableMale and Female15Phase 1Japan
12ChiCTR-IOR-14005674
2014-12-302014-12-09Open randomized controlled trial of the Jianpi Yifei Decoction in the treatment of bulbar paralysis of amyotrophic lateral sclerosisOpen randomized controlled trial of the Jianpi Yifei Decoction in the treatment of bulbar paralysis of amyotrophic lateral sclerosis amyotrophic lateral sclerosisChinese medicine :Jianpi Yifei Decoction ;Riluzole:Riluzole;Guangdong Province Traditional Chinese Medical HospitalNULLPending1880BothChinese medicine :30;Riluzole:30;China
13JPRN-UMIN000011494
2013/09/0202/09/2013Assessment of the efficacy and the influence on swallowing function of transdermal scopolamine for ALS patinets' droolingAssessment of the efficacy and the influence on swallowing function of transdermal scopolamine for ALS patinets' drooling - SCOPOLA-D amyotrophic lateral sclerosisscopolamine patch 7days-washout 7days-placebo patch 7days
placebo patch 7days-washout 7days-scopolamine patch 7days
Mie University Graduate school of medicine,Department of neurologyMatsusaka Chuou HospitalNational Mie HospitalComplete: follow-up completeNot applicableNot applicableMale and Female10Not applicableJapan
14JPRN-UMIN000006423
2011/10/0101/10/2011The clinical trial to assess efficacy of mexiletine for amyotrophic lateral sclerosisThe clinical trial to assess efficacy of mexiletine for amyotrophic lateral sclerosis - Mexiletine on amyotrophic lateral sclerosis amyotrophic lateral sclerosisadministration of mexiletine and riluzole
administration of riluzole only
Department of Neurology, Graduate School of Medicine, Chiba University, Japan.NULLComplete: follow-up complete20years-oldNot applicableMale and Female60Not selectedJapan
15EUCTR2010-024423-24-IE
(EUCTR)
06/11/2014A controlled clinical study to investigate the effectiveness and safety of the medicine called masitinib when used together with a currently available medicine Riluzole when treating the illness called Amyotrophic Lateral Sclerosis (ALS)A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2/3 Study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS). - IRELAND Phase 2/3 study comparing Masitinib/Placebo in ALS Amyotrophic lateral Sclerosis
MedDRA version: 18.0;Level: PT;Classification code 10028003;Term: Motor neurone disease;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 18.0;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Masitinib 100 mg Tablets
Product Code: AB1010
INN or Proposed INN: Masitinib mesylate
Other descriptive name: SUB126308
Product Name: Masitinib 200 mg Tablets
Product Code: AB1010
INN or Proposed INN: Masitinib mesylate
Other descriptive name: SUB126308
AB ScienceNULLNot RecruitingFemale: yes
Male: yes
381Phase 2;Phase 3Portugal;United States;Slovakia;Greece;Spain;Ireland;Colombia;Italy;Switzerland;United Kingdom;France;Hungary;Mexico;Argentina;Belgium;Romania;Netherlands;Germany